188 related articles for article (PubMed ID: 21930798)
1. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.
Barry EL; Mott LA; Sandler RS; Ahnen DJ; Baron JA
Cancer Prev Res (Phila); 2011 Dec; 4(12):2072-82. PubMed ID: 21930798
[TBL] [Abstract][Full Text] [Related]
2. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Barry EL; Baron JA; Bhat S; Grau MV; Burke CA; Sandler RS; Ahnen DJ; Haile RW; O'Brien TG
J Natl Cancer Inst; 2006 Oct; 98(20):1494-500. PubMed ID: 17047198
[TBL] [Abstract][Full Text] [Related]
3. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge MJ; Houlston RS;
Clin Cancer Res; 2008 Apr; 14(8):2303-9. PubMed ID: 18413818
[TBL] [Abstract][Full Text] [Related]
4. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
Martinez ME; O'Brien TG; Fultz KE; Babbar N; Yerushalmi H; Qu N; Guo Y; Boorman D; Einspahr J; Alberts DS; Gerner EW
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7859-64. PubMed ID: 12810952
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
Barry EL; Poole EM; Baron JA; Makar KW; Mott LA; Sandler RS; Ahnen DJ; Bresalier RS; McKeown-Eyssen GE; Ulrich CM
Cancer Causes Control; 2013 Jan; 24(1):47-54. PubMed ID: 23081681
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Barry EL; Sansbury LB; Grau MV; Ali IU; Tsang S; Munroe DJ; Ahnen DJ; Sandler RS; Saibil F; Gui J; Bresalier RS; McKeown-Eyssen GE; Burke C; Baron JA
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2726-33. PubMed ID: 19755647
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
8. Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.
Figueiredo JC; Levine AJ; Grau MV; Midttun O; Ueland PM; Ahnen DJ; Barry EL; Tsang S; Munroe D; Ali I; Haile RW; Sandler RS; Baron JA
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2136-45. PubMed ID: 18708408
[TBL] [Abstract][Full Text] [Related]
9. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
Zell JA; McLaren CE; Chen WP; Thompson PA; Gerner EW; Meyskens FL
J Natl Cancer Inst; 2010 Oct; 102(19):1513-6. PubMed ID: 20798393
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
Chan AT; Tranah GJ; Giovannucci EL; Hunter DJ; Fuchs CS
J Natl Cancer Inst; 2005 Mar; 97(6):457-60. PubMed ID: 15770010
[TBL] [Abstract][Full Text] [Related]
11. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.
Nan H; Hutter CM; Lin Y; Jacobs EJ; Ulrich CM; White E; Baron JA; Berndt SI; Brenner H; Butterbach K; Caan BJ; Campbell PT; Carlson CS; Casey G; Chang-Claude J; Chanock SJ; Cotterchio M; Duggan D; Figueiredo JC; Fuchs CS; Giovannucci EL; Gong J; Haile RW; Harrison TA; Hayes RB; Hoffmeister M; Hopper JL; Hudson TJ; Jenkins MA; Jiao S; Lindor NM; Lemire M; Le Marchand L; Newcomb PA; Ogino S; Pflugeisen BM; Potter JD; Qu C; Rosse SA; Rudolph A; Schoen RE; Schumacher FR; Seminara D; Slattery ML; Thibodeau SN; Thomas F; Thornquist M; Warnick GS; Zanke BW; Gauderman WJ; Peters U; Hsu L; Chan AT; ;
JAMA; 2015 Mar; 313(11):1133-42. PubMed ID: 25781442
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta.
Siezen CL; Tijhuis MJ; Kram NR; van Soest EM; de Jong DJ; Fodde R; van Kranen HJ; Kampman E
Pharmacogenet Genomics; 2006 Jan; 16(1):43-50. PubMed ID: 16344721
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge M; Armitage N; Shepherd V; Popat S; Houlston RS;
Clin Cancer Res; 2006 Nov; 12(21):6585-9. PubMed ID: 17085674
[TBL] [Abstract][Full Text] [Related]
14. Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.
Sheth H; Northwood E; Ulrich CM; Scherer D; Elliott F; Barrett JH; Forman D; Wolf CR; Smith G; Jackson MS; Santibanez-Koref M; Haile R; Casey G; Jenkins M; Win AK; Hopper JL; Marchand LL; Lindor NM; Thibodeau SN; Potter JD; Burn J; Bishop DT
PLoS One; 2018; 13(2):e0192223. PubMed ID: 29425227
[TBL] [Abstract][Full Text] [Related]
15. [Aspirin for Chemoprevention of Colorectal Adenoma and Cancer].
Ishikawa H
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1425-1428. PubMed ID: 34911904
[TBL] [Abstract][Full Text] [Related]
16. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.
Zell JA; Ziogas A; Ignatenko N; Honda J; Qu N; Bobbs AS; Neuhausen SL; Gerner EW; Anton-Culver H
Clin Cancer Res; 2009 Oct; 15(19):6208-16. PubMed ID: 19789310
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies JR; Mell T; Fuller H; Harland M; Saleh RNM; Race AD; Rees CJ; Brown LC; Loadman PM; Downing A; Minihane AM; Williams EA; Hull MA
Cancer Prev Res (Phila); 2023 Nov; 16(11):621-629. PubMed ID: 37756582
[TBL] [Abstract][Full Text] [Related]
18. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
Chan AT; Hsu M; Zauber AG; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2012 Jan; 5(1):61-72. PubMed ID: 22030088
[TBL] [Abstract][Full Text] [Related]
19. Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial.
Passarelli MN; Barry EL; Rees JR; Mott LA; Ahnen DJ; Baron JA
Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1262-1265. PubMed ID: 31263057
[TBL] [Abstract][Full Text] [Related]
20. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Cole BF; Baron JA; Sandler RS; Haile RW; Ahnen DJ; Bresalier RS; McKeown-Eyssen G; Summers RW; Rothstein RI; Burke CA; Snover DC; Church TR; Allen JI; Robertson DJ; Beck GJ; Bond JH; Byers T; Mandel JS; Mott LA; Pearson LH; Barry EL; Rees JR; Marcon N; Saibil F; Ueland PM; Greenberg ER;
JAMA; 2007 Jun; 297(21):2351-9. PubMed ID: 17551129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
